Table 1.
Demographic and clinical characteristics of 1377 patients with RMD, stratified by disease flare requiring treatment or no flare from D1 SARS-CoV-2 mRNA vaccine up to 1 month after D2.
| Overall (n=1377) | Disease flare (n=151) | No disease flare (n=1226) | p-value1 | |
|---|---|---|---|---|
| Age, median (IQR) | 47 (37, 59) | 46 (36, 57) | 47 (37, 60) | 0.2 |
| Female sex, no. (%)2 | 1266 (92) | 144 (95) | 1122 (92) | 0.1 |
| Non-white, no. (%)2 | 130 (10) | 8 (5) | 122 (10) | 0.1 |
| Diagnosis, no. (%) | ||||
| Inflammatory arthritis3 | 647 (47) | 73 (48) | 574 (47) | 0.7 |
| Systemic lupus erythematosus | 273 (20) | 30 (20) | 243 (20) | >0.9 |
| Sjogren’s syndrome | 65 (5) | 7 (5) | 58 (5) | >0.9 |
| Myositis | 66 (5) | 6 (4) | 60 (5) | 0.8 |
| Vasculitis | 41 (3) | 7 (5) | 34 (3) | 0.2 |
| Scleroderma | 14 (1) | 2 (1) | 12 (1) | 0.7 |
| Overlap connective tissue disease4 | 271 (20) | 26 (17) | 245 (20) | 0.5 |
| Vaccine, no. (%) | ||||
| BNT162b2 | 755 (55) | 82 (54) | 673 (55) | 0.9 |
| mRNA-1273 | 622 (45) | 69 (46) | 553 (45) | |
| Therapy, no. (%) | ||||
| Conventional DMARD5 | 352 (26) | 23 (15) | 329 (27) | 0.002 |
| Biologic 6 | 303 (22) | 22 (15) | 281 (23) | 0.02 |
| Glucocorticoid monotherapy7 | 35 (3) | 6 (4) | 29 (2) | 0.3 |
| Immunomodulatory monotherapy8 | 6 (0.4) | 1 (1) | 5 (0.4) | - |
| Combination9 | 681 (50) | 99 (66) | 582 (48) | <0.001 |
| Flare in 6 months prior to vaccine, no. (%) | 767 (56) | 113 (75) | 654 (53) | <0.001 |
| Prior COVID-19 diagnosis, no. (%) | 50 (3) | 11 (7) | 39 (3) | 0.02 |
Comparisons between disease flare and no disease flare groups, categories with an overall n<10 were not analyzed
The denominators for these categories differ from the total N as 1 participant selected “prefer not to answer” for sex and 23 selected “prefer not to answer” for race
Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis and inflammatory bowel disease associated arthritis
Overlap denotes a combination of two or more of the above conditions
Azathioprine, hydroxychloroquine, leflunomide, methotrexate, mycophenolate, sulfasalazine, and tacrolimus
Abatacept, adalimumab, anakinra, baricitinib, belimumab, certolizumab, etanercept, golimumab, infliximab, ixekizumab, rituximab, secukinumab, tocilizumab, tofacitinib, upadacitinib, and ustekinumab
Prednisone and prednisone equivalents
Intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg), a p-value was not calculated as sample too small
Denotes cDMARD and biologic and/or glucocorticoid, or biologic and glucocorticoid